1.Discrepancies between Glycosylated Hemoglobin and Fasting Plasma Glucose for Diagnosing Impaired Fasting Glucose and Diabetes Mellitus in Korean Youth and Young Adults
Jieun LEE ; Young Ah LEE ; Jae Hyun KIM ; Seong Yong LEE ; Choong Ho SHIN ; Sei Won YANG
Diabetes & Metabolism Journal 2019;43(2):174-182
BACKGROUND: Glycosylated hemoglobin (HbA1c) has been recommended as a diagnostic test for prediabetes and diabetes. Here, we evaluated the level of agreement between diagnoses based on fasting plasma glucose (FPG) versus HbA1c levels and determined optimal HbA1c cutoff values for these diseases in youth and young adults. METHODS: The study included 7,332 subjects (n=4,129, aged 10 to 19 years in youth group; and n=3,203 aged 20 to 29 years in young adult group) from the 2011 to 2016 Korea National Health and Nutrition Examination Survey. Prediabetes and diabetes were defined as 100 to 125 mg/dL (impaired fasting glucose [IFG]) and ≥126 mg/dL for FPG (diabetes mellitus [DM] by FPG [DMFPG]), and 5.7% to 6.4% and ≥6.5% for HbA1c, respectively. RESULTS: In the youth group, 32.5% with IFG had an HbA1c level of 5.7% to 6.4%, and 72.2% with DMFPG had an HbA1c ≥6.5%. In the young adult group, 27.5% with IFG had an HbA1c level of 5.7% to 6.4%, and 66.6% with DMFPG had an HbA1c ≥6.5%. Kappa coefficients for agreement between the FPG and HbA1c results were 0.12 for the youth group and 0.19 for the young adult group. In receiver operating characteristic curve analysis, the optimal HbA1c cutoff for IFG and DMFPG were 5.6% and 5.9% in youths and 5.5% and 5.8% in young adults, respectively. CONCLUSION: Usefulness of HbA1c for diagnosis of IFG and DMFPG in Koreans aged <30 years remains to be determined due to discrepancies between the results of glucose- and HbA1c-based tests. Additional testing might be warranted at lower HbA1c levels to detect IFG and DMFPG in this age group.
Adolescent
;
Blood Glucose
;
Diabetes Mellitus
;
Diagnosis
;
Diagnostic Tests, Routine
;
Fasting
;
Glucose
;
Hemoglobin A, Glycosylated
;
Humans
;
Korea
;
Nutrition Surveys
;
Plasma
;
Prediabetic State
;
ROC Curve
;
Young Adult
2.Association between hemoglobin glycation index and cardiometabolic risk factors in Korean pediatric nondiabetic population.
Bora LEE ; You Jung HEO ; Young Ah LEE ; Jieun LEE ; Jae Hyun KIM ; Seong Yong LEE ; Choong Ho SHIN ; Sei Won YANG
Annals of Pediatric Endocrinology & Metabolism 2018;23(4):196-203
PURPOSE: The hemoglobin glycation index (HGI) represents the degree of nonenzymatic glycation and has been positively associated with cardiometabolic risk factors (CMRFs) and cardiovascular disease in adults. This study aimed to investigate the association between HGI, components of metabolic syndrome (MS), and alanine aminotransferase (ALT) in a pediatric nondiabetic population. METHODS: Data from 3,885 subjects aged 10–18 years from the Korea National Health and Nutrition Examination Survey (2011–2016) were included. HGI was defined as subtraction of predicted glycated hemoglobin (HbA1(c)) from measured HbA1(c). Participants were divided into 3 groups according to HGI tertile. Components of MS (abdominal obesity, fasting glucose, triglycerides, high-density lipoprotein cholesterol, and blood pressure), and proportion of MS, CMRF clustering (≥2 of MS components), and elevated ALT were compared among the groups. RESULTS: Body mass index (BMI) z-score, obesity, total cholesterol, ALT, abdominal obesity, elevated triglycerides, and CMRF clustering showed increasing HGI trends from lower-to-higher tertiles. Multiple logistic regression analysis showed the upper HGI tertile was associated with elevated triglycerides (odds ratio, 1.65; 95% confidence interval, 1.18–2.30). Multiple linear regression analysis showed HGI level was significantly associated with BMI z-score, HbA1(c), triglycerides, and ALT. When stratified by sex, age group, and BMI category, overweight/obese subjects showed linear HGI trends for presence of CMRF clustering and ALT elevation. CONCLUSIONS: HGI was associated with CMRFs in a Korean pediatric population. High HGI might be an independent risk factor for CMRF clustering and ALT elevation in overweight/obese youth. Further studies are required to establish the clinical relevance of HGI for cardiometabolic health in youth.
Adolescent
;
Adult
;
Alanine Transaminase
;
Body Mass Index
;
Cardiovascular Diseases
;
Cholesterol
;
Fasting
;
Glucose
;
Hemoglobin A, Glycosylated
;
Humans
;
Korea
;
Linear Models
;
Lipoproteins
;
Logistic Models
;
Nutrition Surveys
;
Obesity
;
Obesity, Abdominal
;
Risk Factors*
;
Triglycerides
3.Unfavorable Course of Subclinical Hypothyroidism in Children with Hashimoto's Thyroiditis Compared to Those with Isolated Non-Autoimmune Hyperthyrotropinemia.
Yun Jeong LEE ; So Yoon JUNG ; Hae Woon JUNG ; So Youn KIM ; Young Ah LEE ; Seong Yong LEE ; Choong Ho SHIN ; Sei Won YANG
Journal of Korean Medical Science 2017;32(1):124-129
Subclinical hypothyroidism (SCH) is a common problem in pediatric population, and the natural history of SCH varies depending on its etiology. Whether Hashimoto’s thyroiditis (HT) negatively affects the natural course of SCH was investigated in pediatric patients without concomitant diseases. Predictors for levothyroxine medication were also evaluated. Medical records of 109 children with SCH (91 girls, 5−18 years) diagnosed between 2005 and 2014 were retrospectively reviewed. Patients were classified into HT (n = 37) and isolated non-autoimmune hyperthyrotropinemia (iso-NAHT, n = 72). During median 2 years of follow-up, only 10.1% of SCH patients eventually initiated levothyroxine, and HT patients showed a higher probability of requiring levothyroxine medication than iso-NAHT patients (21.6% vs. 4.2%). Underlying HT independently predicted deterioration of thyroid function, leading to levothyroxine medication (hazard ratios [HRs], 4.6 vs. iso-NAHT, P = 0.025). High titers of anti-thyroglobulin antibodies (TGAbs) predicted later medication in the HT group (HRs, 28.2 vs. normal TGAbs, P = 0.013). Most pediatric SCH showed benign and self-remitting courses. Underlying HT significantly increases the risk for levothyroxine medication, especially with high titers of TGAbs.
Antibodies
;
Child*
;
Female
;
Follow-Up Studies
;
Hashimoto Disease
;
Humans
;
Hypothyroidism*
;
Medical Records
;
Natural History
;
Retrospective Studies
;
Thyroid Diseases
;
Thyroid Gland*
;
Thyroiditis*
;
Thyroxine
4.Factors Associated with the Presence and Severity of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Korean Children and Adolescents.
Hye Jin LEE ; Hyeoh Won YU ; Hae Woon JUNG ; Young Ah LEE ; Jae Hyun KIM ; Hye Rim CHUNG ; Jaeho YOO ; Eunyoung KIM ; Jeesuk YU ; Choong Ho SHIN ; Sei Won YANG ; Seong Yong LEE
Journal of Korean Medical Science 2017;32(2):303-309
The aim of this study was to identify the risk factors for presence and severity of diabetic ketoacidosis (DKA) at the onset of type 1 diabetes mellitus (T1DM) in Korean children and adolescents. A retrospective chart review of children and adolescents newly diagnosed with T1DM was conducted in seven secondary and tertiary centers in Korea. Eligible subjects were < 20 years of age and had records on the presence or absence of DKA at the time of T1DM diagnosis. DKA severity was categorized as mild, moderate, or severe. Data were collected on age, height, body weight, pubertal status, family history of diabetes, delayed diagnosis, preceding infections, health insurance status, and parental education level. A total of 361 patients (male 46.3%) with T1DM were included. Overall, 177 (49.0%) patients presented with DKA at T1DM diagnosis. Risk factors predicting DKA at T1DM diagnosis were age ≥ 12 years, lower serum C-peptide levels, presence of a preceding infection, and delayed diagnosis. Low parental education level and preceding infection increased the severity of DKA. These results suggest that alertness of the physician and public awareness of diabetes symptoms are needed to decrease the incidence and severity of DKA at T1DM diagnosis.
Adolescent*
;
Body Height
;
C-Peptide
;
Child*
;
Delayed Diagnosis
;
Diabetes Mellitus, Type 1
;
Diabetic Ketoacidosis*
;
Diagnosis*
;
Education
;
Humans
;
Incidence
;
Insurance, Health
;
Korea
;
Parents
;
Retrospective Studies
;
Risk Factors
5.Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients.
Ji Yong JANG ; Sang Hak LEE ; Byung Soo KIM ; Hong Seog SEO ; Woo Shik KIM ; Youngkeun AHN ; Nae Hee LEE ; Kwang Kon KOH ; Tae Soo KANG ; Sang Ho JO ; Bum Kee HONG ; Jang Ho BAE ; Hyoung Mo YANG ; Kwang Soo CHA ; Bum Soo KIM ; Choong Hwan KWAK ; Deok Kyu CHO ; Ung KIM ; Joo Hee ZO ; Duk Hyun KANG ; Wook Bum PYUN ; Kook Jin CHUN ; June NAMGUNG ; Tae Joon CHA ; Jae Hyeon JUHN ; Yeili JUNG ; Yangsoo JANG
Korean Circulation Journal 2015;45(3):225-233
BACKGROUND AND OBJECTIVES: We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. SUBJECTS AND METHODS: Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: valsartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvastatin 20 mg plus placebo. The primary efficacy variables were change in sitting diastolic blood pressure (sitDBP) and sitting systolic blood pressure (sitSBP), and percentage change in low-density lipoprotein-cholesterol (LDL-C) in the combination, valsartan, and rosuvastatin groups. Adverse events (AEs) during the study were analyzed. RESULTS: A total of 354 patients were screened and 123 of them were finally randomized. Changes of sitDBP by least squares mean (LSM) were -11.1, -7.2, and -3.6 mm Hg, respectively, and was greater in the combination, as compared to both valsartan (p=0.02) and rosuvastatin (p<0.001). Changes of sitSBP by LSM were -13.2, -10.8, and -4.9 mm Hg, and was greater in the combination, as compared to rosuvastatin (p=0.006) and not valsartan (p=0.42). Percentage changes of LDL-C by LSM were -52, -4, and -47% in each group, and was greater in the combination, as compared to valsartan (p<0.001), similar to rosuvastatin (p=0.16). Most AEs were mild and resolved by the end of the study. CONCLUSION: Combination treatment with valsartan and rosuvastatin exhibited an additive blood pressure-lowering effect with acceptable tolerability, as compared to valsartan monotherapy. Its lipid lowering effect was similar to rosuvatatin monotherapy.
Blood Pressure
;
Drug Therapy, Combination
;
Humans
;
Least-Squares Analysis
;
Rosuvastatin Calcium
;
Valsartan
6.Recurrent Stent Thrombosis in a Patient with Antiphospholipid Syndrome and Dual Anti-Platelet Therapy Non-Responsiveness.
You Hong LEE ; Hyoung Mo YANG ; Seung Jea TAHK ; You Sun HONG ; Jin Sun PARK ; Kyoung Woo SEO ; Yong Woo CHOI ; Choong Kyun NOH
Korean Circulation Journal 2015;45(1):71-76
Antiphospholipid syndrome (APS), the most common acquired hypercoagulable condition, is diagnosed by persistent presence of antiphospholipid antibodies and episodes of vascular thrombosis. It may be an important predisposing factor for stent thrombosis, resulting in poor outcomes. Also, anti-platelet therapy non-responsiveness is associated with stent thrombosis. We report a case of a 39-year-old man who after undergoing successful percutaneous coronary intervention for significant coronary artery disease suffered repeated stent thrombosis events leading to ST-segment elevation myocardial infarction. Eventually, he underwent coronary artery bypass surgery because of uncontrolled thrombosis and was diagnosed as having APS and dual antiplatelet therapy non-responsiveness.
Adult
;
Antibodies, Antiphospholipid
;
Antiphospholipid Syndrome*
;
Causality
;
Coronary Artery Bypass
;
Coronary Artery Disease
;
Humans
;
Myocardial Infarction
;
Percutaneous Coronary Intervention
;
Stents*
;
Thrombosis*
7.Erratum to: Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients.
Ji Yong JANG ; Sang Hak LEE ; Byung Soo KIM ; Hong Seog SEO ; Woo Shik KIM ; Youngkeun AHN ; Nae Hee LEE ; Kwang Kon KOH ; Tae Soo KANG ; Sang Ho JO ; Bum Kee HONG ; Jang Ho BAE ; Hyoung Mo YANG ; Kwang Soo CHA ; Bum Soo KIM ; Choong Hwan KWAK ; Deok Kyu CHO ; Ung KIM ; Joo Hee ZO ; Duk Hyun KANG ; Wook Bum PYUN ; Kook Jin CHUN ; June NAMGUNG ; Tae Joon CHA ; Jae Hyeon JUHN ; YeiLi JUNG ; Yangsoo JANG
Korean Circulation Journal 2015;45(4):349-349
In this article, on page 230, Fig. 2A needs to be corrected.
8.Clinical and radiological features of pituitary stalk lesions in children and adolescents.
Sung Chul YOON ; Choong Ho SHIN ; Sei Won YANG ; Seong Yong LEE
Annals of Pediatric Endocrinology & Metabolism 2014;19(4):202-207
PURPOSE: The diagnosis of pituitary stalk lesion has been based on clinical feature, radiologic assessment for its critical location and role. This study aimed to investigate clinical symptoms, endocrine disturbance, magnetic resonance imaging (MRI) findings of pituitary stalk lesions in children and adolescents and to evaluate differences between neoplastic lesions with the others. METHODS: We performed a retrospective review of patients under 18 years old with pituitary stalk lesions diagnosed at the Seoul National University Children's Hospital between 2000 and 2013, by a text search for head MRI reports by using 'pituitary stalk', 'infundibulum', and 'infundibular stalk', as keywords. RESULTS: For the 76 patients, sixteen patients (21.1%) had congenital lesions, and 52 (68.4%) had neoplasms. No inflammatory lesions were found. Diabetes insipidus (DI) was the most common endocrine defect, diagnosed in 38 patients (50%). There was male predominance especially in neoplastic group. Thickened pituitary stalk was, but enhancement of lesion was not, associated with neoplasm. DI was more prevalent in neoplastic stalk lesions. Anterior pituitary dysfunction such as growth hormone and adrenocorticotropic hormone deficiencies were less prevalent in neoplastic lesions of pituitary stalk. CONCLUSION: In conclusion, the etiology of pituitary stalk lesions in children and adolescents is diverse and different from that in adults. Neoplastic pituitary stalk lesions can be differentiated from nonneoplastic lesions by systemic evaluation of clinical, hormonal, radiological findings.
Adolescent*
;
Adrenocorticotropic Hormone
;
Adult
;
Child*
;
Diabetes Insipidus
;
Diagnosis
;
Growth Hormone
;
Head
;
Humans
;
Magnetic Resonance Imaging
;
Male
;
Pituitary Gland*
;
Pituitary Hormones
;
Retrospective Studies
;
Seoul
9.Influence of Body Mass Index on the Growth Hormone Response to Provocative Testing in Short Children without Growth Hormone Deficiency.
Jieun LEE ; Juyoung YOON ; Min Jae KANG ; Young Ah LEE ; Seong Yong LEE ; Choong Ho SHIN ; Sei Won YANG
Journal of Korean Medical Science 2013;28(9):1351-1355
Obesity and its related factors are known to suppress the secretion of growth hormone (GH). We aimed to evaluate the influence of body mass index (BMI) on the peak GH response to provocative testing in short children without GH deficiency. We conducted a retrospective review of medical records of 88 children (2-15 yr old) whose height was less than 3 percentile for one's age and sex, with normal results (peak GH level > 10 ng/mL) of GH provocative testing with clonidine and dopamine. Peak stimulated GH level, height, weight, pubertal status and serum IGF-1 level were measured. Univariate analysis showed that the BMI standard deviation score (SDS) correlated negatively with the natural log (ln) of the peak stimulated GH level (ln peak GH). BMI SDS did not correlate significantly with sex, age, pubertal status, or ln IGF-1 level. BMI SDS correlated negatively with ln peak GH level induced by clonidine but not by dopamine. In stepwise multivariate regression analysis, BMI SDS was the only significant predictor of ln peak GH level in the combination of tests and the clonidine test, but not in the dopamine test. In children without GH deficiency, BMI SDS correlates negatively with the peak GH level. BMI SDS should be included in the analysis of the results of GH provocation tests, especially tests with clonidine.
Adolescent
;
Body Height
;
*Body Mass Index
;
Body Weight
;
Child
;
Child, Preschool
;
Clonidine/therapeutic use
;
Dopamine/therapeutic use
;
Dwarfism/drug therapy
;
Female
;
Human Growth Hormone/*analysis
;
Humans
;
Insulin-Like Growth Factor I/analysis
;
Male
;
Regression Analysis
;
Retrospective Studies
10.Growth after Hematopoietic Stem Cell Transplantation in Children with Acute Myeloid Leukemia.
Seung Joon CHUNG ; Seung Wan PARK ; Min Kyoung KIM ; Min Jae KANG ; Young Ah LEE ; Seong Yong LEE ; Choong Ho SHIN ; Sei Won YANG ; Hyoung Jin KANG ; Kyung Duk PARK ; Hee Young SHIN ; Hyo Seop AHN
Journal of Korean Medical Science 2013;28(1):106-113
Previous studies have shown that hematopoietic stem cell transplantation (HSCT) may result in growth impairment. The purpose of this study was to evaluate the growth during 5 yr after HSCT and to determine factors that influence final adult height (FAH). We retrospectively reviewed the medical records of acute myeloid leukemia (AML) patients who received HSCT. Among a total of 37 eligible patients, we selected 24 patients who began puberty at 5 yr after HSCT (Group 1) and 19 patients who reached FAH without relapse (Group 2). In Group 1, with younger age at HSCT, sex, steroid treatment, hypogonadism and hypothyroidism were not significantly associated with growth impairment 5 yr after HSCT. History of radiotherapy (RT) significantly impaired the 5 yr growth after HSCT. Chronic graft-versus-host disease (cGVHD) only temporarily impaired growth after HSCT. In Group 2, with younger age at HSCT, steroid treatment and hypogonadism did not significantly reduce FAH. History of RT significantly reduced FAH. Growth impairment after HSCT may occur in AML patients, but in patients without a history of RT, growth impairment seemed to be temporary and was mitigated by catch-up growth.
Adolescent
;
Body Height/*radiation effects
;
Child
;
Child, Preschool
;
Female
;
Graft vs Host Disease/pathology/prevention & control
;
*Hematopoietic Stem Cell Transplantation
;
Humans
;
Hypogonadism/drug therapy/pathology
;
Infant
;
Leukemia, Myeloid, Acute/radiotherapy/*therapy
;
Male
;
Recurrence
;
Retrospective Studies
;
Risk Factors
;
Steroids/therapeutic use

Result Analysis
Print
Save
E-mail